Related references
Note: Only part of the references are listed.Age-dependent impairment in antibody responses elicited by a homologous CoronaVac booster dose
Bruno Andraus Filardi et al.
SCIENCE TRANSLATIONAL MEDICINE (2023)
Prediction of long-term kinetics of vaccine-elicited neutralizing antibody and time-varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint
Xinhua Chen et al.
BMC MEDICINE (2022)
Dynamics of antibody response to CoronaVac vaccine
Marcela Helena Gambim Fonseca et al.
JOURNAL OF MEDICAL VIROLOGY (2022)
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study
Sue Ann Costa Clemens et al.
LANCET (2022)
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial
Arabella S. Stuart et al.
LANCET (2022)
Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials
Gang Zeng et al.
LANCET INFECTIOUS DISEASES (2022)
Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination
Samuel M. S. Cheng et al.
NATURE MEDICINE (2022)
Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial
Jingxin Li et al.
NATURE MEDICINE (2022)
Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination
Eddy Perez-Then et al.
NATURE MEDICINE (2022)
Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong
Chris Ka Pun Mok et al.
RESPIROLOGY (2022)
Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study
Denis Saure et al.
LANCET INFECTIOUS DISEASES (2022)
The COVID-19 Humoral Immunological Status Induced by CoronaVac and AstraZeneca Vaccines Significantly Benefits from a Booster Shot with the Pfizer Vaccine
Jessica Pires Farias et al.
JOURNAL OF VIROLOGY (2022)
Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant
Fanglei Zuo et al.
NATURE COMMUNICATIONS (2022)
Booster Doses of Anti COVID-19 Vaccines: An Overview of Implementation Policies among OECD and EU Countries
Fabrizio Bert et al.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2022)
Relative Vaccine Effectiveness of the Third Dose of CoronaVac or BNT162b2 Following a Two-Dose CoronaVac Regimen: A Prospective Observational Cohort Study from an Adult Vaccine Center in Turkey
Meliha Cagla Sonmezer et al.
VACCINES (2022)
Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19
Wey Wen Lim et al.
LANCET MICROBE (2021)
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial
Alasdair P S Munro et al.
LANCET (2021)
Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data
Robert H Shaw et al.
LANCET (2021)
Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination
Joana Barros-Martins et al.
NATURE MEDICINE (2021)
Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals
Ling Ni et al.
IMMUNITY (2020)